Skip to content

Point of care testing for urinary tract infection in primary care: Stages 3 & 4

Point of care testing for urinary tract infection in primary care: Stages 3 & 4 - a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65200697
Enrollment
614
Registered
2013-09-10
Start date
2013-07-23
Completion date
Unknown
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Primary Care Research Network for England

Interventions

Current interventions as of 12/12/2016: Intervention arm: Participants randomised to the experimental intervention arm will have their treatment guided by the Flexicult

Sponsors

Cardiff University (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 years and above presenting with suspected uncomplicated urinary tract infection. 2. Presenting with at least one of three key urinary tract symptoms (dysuria, urgency including nocturia, and frequency) 3. Able to provide informed consent and willing to complete a patient diary.

Exclusion criteria

Exclusion criteria: Added 12/12/2016: 1. Terminally ill 2. Currently receiving treatment for life-threatening cancer (basal cell carcinoma, for example, excluded) 3. Other severe systemic symptoms, such as high fever, renal angle pain, rigors 4. On long-term antibiotic treatment or have received antibiotics for urinary tract infection within the past four weeks 5. Has had bladder surgery (including cystoscopy) within the past four weeks 6. Known or likely to have significant immune compromise (i.e. known immunodeficiency state, on long-term corticosteroid or chemotherapy treatment, insulin dependent diabetes) 7. Known functional or anatomical abnormalities of the genitourinary tract 8. History of pyelonephritis 9. Known pregnancy 10. Unable to provide a urine sample on the day of first presentation

Design outcomes

Primary

MeasureTime frame
Appropriate antibiotic use, defined as consumption of an antibiotic on day three (or days one or two for fosfomycin) for which a pathogen considered to be causing a UTI isolated in a laboratory was sensitive in vitro, and no antibiotic use by those women who did not have a UTI on laboratory culture

Secondary

MeasureTime frame
Added 12/12/2016: 1. Severity of 11 signs and symptoms, rated by clinicians using a scale of zero (normal/not affected) to six (as bad as it could be, at day 14 and 3 months 2. Participant-rated severity of symptoms and antibiotic use, recorded in a patient diary on each of the 14 days 3. How patients are able to cope with and understand their illness, measured using the Patient Enablement Instrument at day 14 and 3 months

Countries

Netherlands, Spain, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 7, 2026